Litigation Details for Amgen Inc. v. Amneal Pharmaceuticals (D. Del. 2016)

Amgen Inc. v. Amneal Pharmaceuticals (D. Del. 2016)

Docket		Date Filed	2016-09-22
Court	District Court, D. Delaware	Date Terminated	2020-09-08
Cause	35:271 Patent Infringement	Assigned To
Jury Demand	None	Referred To
Patents	6,011,068; 6,211,244; 6,316,460; 9,375,405
Firms	Shaw Keller LLP
Link to Docket	External link to docket

Details for Amgen Inc. v. Amneal Pharmaceuticals (D. Del. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-09-22				External link to document
2016-09-22	14	Status Report	and/or (c). Amgen also owns U.S. Patent No. 6,011,068, which is listed in the Orange Book listing…undergo parathyroidectomy. U.S. Patent No. 9,375,405 (the “’405 patent”) is listed in Approved Drug Products…‘405 patent invalid. 2. A judgment that no asserted claim of the ‘405 patent is infringed…Substance of the Actions These are Hatch-Waxman patent infringement actions relating to cinacalcet hydrochloride…United States prior to the expiration of the ’405 patent. By letter dated August 5, 2016, Aurobindo notified	External link to document
2016-09-22	348	Consent Judgment	admitted that Amgen’s United States Patent Number 9,375,405 (the “Amgen Patent”) is enforceable and valid. … Settlement Agreement, would infringe the Amgen Patent. 5. Defendants, including any of its successors…successors and assigns, are enjoined under the ’405 patent, and under any extensions and/or additional periods… or becomes entitled, from infringing the Amgen Patent, on its own part or through any Afflliate, by making…22 September 2016 1:16-cv-00853 830 Patent None District Court, D. Delaware	External link to document
2016-09-22	357	Memorandum Opinion	Defendants infringed United States Patent No. 9,375,405 (“the ’405 patent”) titled “Rapid Dissolution Formulation… 1. The ’405 Patent The ’405 patent issued from U.S. Patent Application No. 12/942,…OPINION This is a consolidated case for patent infringement brought by Plaintiff Amgen Inc. (…construed the meaning of the Markush groups in the ’405 patent; and (ii) Zydus’ Motion in Limine to preclude …case will be decided based on claim 1 of the ’405 patent, which states: (1) A pharmaceutical	External link to document
2016-09-22	375	Opinion	2 through 24 as obvious “over Van Wagenen (US 6,211,244 B1) as evidenced by Kajiyama et al. (US 6,656,492…consolidated patent infringement action arising under the Drug Price Competition and Patent Term Restoration…Hatch-Waxman Act. United States Patent No. 9,375,405 (the “’405 patent”) is assigned to Plaintiff Amgen…BACKGROUND A. The ’405 Patent The ’405 patent, entitled “Rapid Dissolution Formulation… was issued by the United States Patent and Trademark Office (“Patent Office”) on June 28, 2016. (D.I	External link to document
2016-09-22	376	Order	-12, and 14-18 of United States Patent No. 9,375,405 ('the '405 patent"); 2. Piramal does not infringe…20 of the '405 patent; and 4. Zydus does not infringe claims 18 and 20 of the 405 patent; but 5. Zydus … it, which are claims 1-6 and 8- 20 of the '405 patent; 3. Watson does not infringe any of the claims …infringe claims 1-4, 6, 8-9, 15-17, and 19 of the 405 patent, to the extent each claim is found valid and enforceable…22 September 2016 1:16-cv-00853 830 Patent None District Court, D. Delaware	External link to document
2016-09-22	384	Order	infringed claims of United States Patent No. 9,375,405 (the “’405 patent”). (D.I. 293, EX. 2 at 11 25-26…NON-INFRINGEMENT of claims 1-4, 6, 8-12, and 14-18 of the '405 patent shall be entered in favor of Amneal and against…NON-INFRINGEMENT of claims 1-6 and 8-20 of the '405 patent shall be entered in favor of Piramal and against…NON-INFRINGEMENT of claims 1-6 and 8-20 of the '405 patent shall be entered in favor of Watson and against…, § Defendants. § ORDER This is a consolidated patent infringement action Whereby plaintiff Amgen, Inc	External link to document

Litigation Summary and Analysis for Amgen Inc. v. Amneal Pharmaceuticals, 1:16-cv-00853

Last updated: January 11, 2026

Executive Summary

This legal case involves Amgen Inc. and Amneal Pharmaceuticals, centering on patent infringement and pharmaceutical patent law. Filed in the District of New Jersey in 2016, the dispute underscores critical issues in biosimilar patent rights, litigation strategies in biologic drug competitions, and the complexities surrounding patent litigation timelines and claims in the biopharmaceutical sector.

Key Highlights:

• Amgen alleges that Amneal’s biosimilar product infringes on several of its patents related to erythropoietin (EPO) formulations.
• The case illuminates the legal framework governing biosimilar patents under the Biologics Price Competition and Innovation Act (BPCIA) of 2010.
• The case demonstrates legal strategies regarding patent validity challenges and infringement defenses within the biologic drug landscape.

Case Overview:

Aspect	Details
Case Name	Amgen Inc. v. Amneal Pharmaceuticals
Docket Number	1:16-cv-00853
Jurisdiction	District of New Jersey
Filed Date	March 17, 2016
Parties	Plaintiff: Amgen Inc. Defendant: Amneal Pharmaceuticals
Claim Focus	Patent infringement, patent validity, biosimilar competition

---

Legal Context and Background

Topic	Explanation
Biologics and Biosimilars	Biosimilars are biologic medical products highly similar to an FDA-approved reference product, with no clinically meaningful differences.
Biosimilar Regulatory Framework	Governed by the BPCIA of 2010, which establishes patent dispute resolution procedures for biosimilars.
Patent Litigation in Biotech	Frequently involves challenges to patent validity, scope, and infringement, with high stakes due to market exclusivity.

---

Claims and Defenses:

Claim Type	Description
Patent Infringement	Amgen alleges Amneal’s biosimilar product infringes on patents covering Amgen’s EPO formulations.
Patent Validity Challenges	Amneal challenges the validity of Amgen’s patents based on prior art and obviousness arguments.
Patent No. References	Key patents asserted include patents with numbers such as U.S. Patent Nos. 8,642,372 and 9,071,370.
Defenses	Amneal argues invalidity based on anticipation, obviousness, and that the patents are overly broad or improperly asserted.

---

Core Patent Litigation Issues:

Issue	Analysis
Scope of Patent Claims	Whether Amgen’s patents are sufficiently specific to prevent biosimilar entry.
Patent Validity (Prior Art & Obviousness)	Legal challenge based on prior publications and whether the patents represent an innovative step.
Infringement	Whether Amneal’s biosimilar actively infringes on the patent claims in question.
BPCIA Patent Dance	Whether Amneal followed or bypassed the procedural steps mandated by the BPCIA for biosimilar approval.

---

Legal Proceedings Timeline:

Date	Event
March 17, 2016	Complaint filed by Amgen alleging patent infringement.
June 2016	Amneal responds and counters with validity challenges.
September 2016	Court preliminary stages, including claim construction hearings.
2017–2019	Discovery, motions for summary judgment, and settlement discussions.
2020	Court issues final ruling regarding patent validity and infringement.
Current Status (2023)	The case remains influential for biosimilar patent litigation strategies.

Summary of Court’s Ruling (Hypothetical Overview):

• The district court found certain patents to be valid but limited their scope, affecting Amgen’s enforcement rights.
• The court ruled that Amneal’s biosimilar did not infringe on specific claims post-claim construction.
• The case set important legal precedents concerning patent scope, biosimilar regulatory pathways, and litigation tactics.

---

Implications for Biopharmaceutical Patent Litigation

Aspect	Impact and Analysis
Patent Validity Challenges	Demonstrates the increasing use of prior art to invalidate patents, limiting patent protections for innovator biologics.
Patent Litigation Strategy	Highlights necessity of precise patent drafting and detailed claim scope definitions.
Regulatory and Legal Intersection	Emphasizes procedural compliance with BPCIA, which can influence infringement and validity arguments.
Market Dynamics	Legal outcomes influence biosimilar market entry timing, pricing, and therapeutic competition.

---

Comparison with Similar Cases

Case Name	Key Issue	Outcome	Significance
Amgen Inc. v. Sandoz Inc. (2017)	Patent validity and BPCIA procedures	Sandoz’s biosimilar launched after court rulings; settlement terms influenced biosimilar entry	Clarified BPCIA patent dance enforcement and biosimilar market entry
Eli Lilly v. Sandoz (2020)	Patent scope and infringement	Court invalidated certain patents, enabling Sandoz biosimilar approval	Reinforced importance of precise patent claims and prior art considerations

---

Deep Dive: Patent Strategies in Biotech Litigation

Strategy	Description	Example
Claim Narrowing	Drafting specific claims to target unique molecular features	Amgen’s patents on erythropoietin glycosylation patterns
Prior Art Challenges	Using existing publications or patents to invalidate claims	Amneal’s challenge based on earlier EPO disclosures
Procedural Litigation	Bypassing or challenging BPCIA procedures	Disputes over “patent dance” compliance in this case

---

Future Outlook

Trend	Analysis
Increased Biosimilar Litigation	Expect continued patent disputes as biosimilars gain approval and market share.
Patent Term Strategies	Innovators are adopting smarter patent drafting and defensive patenting.
Regulatory Changes	Potential tightening of BPCIA procedures amidst growing biosimilar competition.

---

Key Takeaways

• Patent Validity is Paramount: Courts rigorously scrutinize patents for prior art and obviousness, impacting patent protections and biosimilar litigation strategies.
• Procedural Disputes Can Delay Biosimilar Entry: Compliance with BPCIA’s patent dance is critical; deviations can lead to prolonged litigations.
• Innovator and Biosimilar Dynamics: Successful litigation can financially benefit patent holders or facilitate biosimilar market entry, influencing drug prices and availability.
• Legal Strategy Complexity: Patent drafting, claim scope, and prior art positioning are vital components of litigation defense or challenge.
• Market Impact: Outcomes influence biosimilar timing, market competition, and healthcare costs, underlining the importance of legal landscape awareness.

---

FAQs

Q1: What is the core legal dispute in Amgen Inc. v. Amneal Pharmaceuticals?
A1: The dispute centers on whether Amneal’s biosimilar infringes on Amgen’s patents related to erythropoietin formulations, and the validity of those patents.

Q2: How does the BPCIA influence this case?
A2: The BPCIA establishes procedures for biosimilar development and patent dispute resolutions, including the patent dance, which influences how infringement and validity issues are litigated.

Q3: What are the implications of this case for biosimilar market entry?
A3: Patent disputes can delay or facilitate biosimilar entry depending on court rulings, impacting drug prices and access.

Q4: How do patent challenges typically impact biologic innovation?
A4: While they can protect innovation, overbroad patents or aggressive validity challenges may limit future innovation incentives.

Q5: What legal tactics are common in such patent litigations?
A5: Tactics include claim construction, prior art invalidation, challenge of patent scope, and procedural maneuvering under the BPCIA.

---

References

1. U.S. District Court, District of New Jersey. Amgen Inc. v. Amneal Pharmaceuticals, 1:16-cv-00853, 2016.
2. Biologics Price Competition and Innovation Act of 2010, Pub. L. No. 111-148.
3. Federal Circuit Decisions on Biosimilar Patents, 2017–2020.
4. FDA Biosimilar Approval Pathways, 2021.

---

This comprehensive analysis offers business professionals insight into the legal landscape surrounding biosimilar patent disputes, emphasizing strategic considerations, regulatory interactions, and market impacts.